INMB - INmune Bio GAAP EPS of -$1.52 beats by $0.14 revenue of $0.37M beats by $0.17M
- INmune Bio press release ( NASDAQ: INMB ): FY GAAP EPS of -$1.52 beats by $0.14 .
- Revenue of $0.37M (+105.6% Y/Y) beats by $0.17M .
- As of December 31, 2022, the Company had cash and cash equivalents of approximately $52.2 million.
- As of March 2, 2023, the Company had approximately 17.9 million common shares outstanding.
For further details see:
INmune Bio GAAP EPS of -$1.52 beats by $0.14, revenue of $0.37M beats by $0.17M